Encompass Health Corporation $EHC Position Reduced by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in Encompass Health Corporation (NYSE:EHC) by 85.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 29,294 shares of the company’s stock after selling 176,350 shares during the period. Squarepoint Ops LLC’s holdings in Encompass Health were worth $3,592,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its position in shares of Encompass Health by 25.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock worth $210,756,000 after acquiring an additional 424,691 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Encompass Health by 6.8% in the second quarter. Alliancebernstein L.P. now owns 2,039,314 shares of the company’s stock worth $250,081,000 after purchasing an additional 129,276 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Encompass Health by 5.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company’s stock worth $189,549,000 after purchasing an additional 93,992 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Encompass Health by 13.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company’s stock worth $184,571,000 after buying an additional 211,707 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Encompass Health by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,773,547 shares of the company’s stock valued at $217,526,000 after buying an additional 8,765 shares during the period. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $107.90 on Wednesday. The company has a market capitalization of $10.86 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.90 and a beta of 0.73. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.14 and a current ratio of 1.14. The stock has a fifty day moving average of $116.84 and a 200-day moving average of $118.68. Encompass Health Corporation has a one year low of $87.85 and a one year high of $127.99.

Encompass Health (NYSE:EHC) last announced its earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. Encompass Health had a return on equity of 17.84% and a net margin of 9.33%.The company had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, equities analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Friday, January 2nd will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is 14.37%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EHC. Bank of America lifted their target price on Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, September 10th. KeyCorp increased their target price on Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Barclays boosted their price target on shares of Encompass Health from $141.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Zacks Research downgraded shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 19th. Finally, Raymond James Financial upgraded shares of Encompass Health to a “strong-buy” rating in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and a consensus price target of $142.86.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.